A broad-spectrum antimicrobial agent belonging to the group of nitrofurans. Resistance to Furamag® develops slowly and does not reach a high degree. Active against gram-positive and gram-negative microbes, pathogenic strains Staphylococcus spp. and other microorganisms resistant to antibiotics. Effective against gram-positive cocci (strepto-, staphylococcus), gram-negative rods (Escherichia coli, Salmonella, Shigella, Proteus, Klebsiella, enterobacteria), protozoa (lamblia). In relation to staphylococci, E.coli, Aerobacter aero genes, Bad. Citrovorum, Proteus mirabilis, Proteus morganii Furamag®, in comparison with other nitrofurans, is more active. Furamag® shows a higher activity towards Enterococcus faecalis, Staphylococcus spp. compared with other groups of antimicrobial drugs.
PThe bacteriostatic concentration of most bacteria is from 1: 100,000 to 1: 200,000. The bactericidal concentration is approximately twice as large. Under the influence of nitrofurans in microorganisms, the respiratory chain and the cycle of tricarboxylic acids (Krebs cycle) are suppressed, as well as the inhibition of other biochemical processes of microorganisms, as a result of which their shell or cytoplasmic membrane is destroyed.As a result of the action of nitrofurans, microorganisms produce fewer toxins, so that an improvement in the general condition of the patient is possible even before the expressed suppression of microflora growth. Nitrofurans, unlike many other antimicrobial agents, not only do not inhibit the immune system of the body, but, on the contrary, activate it (increase the complement titre and the ability of leukocytes to phagocytose microorganisms). Nitrofurans in therapeutic doses stimulate leukopoiesis.